Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
OncoC4 creates a bispecific buzz
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
